<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172325</url>
  </required_header>
  <id_info>
    <org_study_id>ADA.CIN.AJ94</org_study_id>
    <secondary_id>IRCT2015030321315N1</secondary_id>
    <nct_id>NCT03172325</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA</brief_title>
  <official_title>A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active Controlled Clinical Trial to Determine the Non-inferior Efficacy and Safety of CinnoRA® (Adalimumab, CinnaGen Co.) Versus Humira® for Treatment of Active RA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cinnagen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cinnagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of adalimumab produced by&#xD;
      CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis. Patients&#xD;
      with the diagnosis of active Rheumatoid arthritis according to EULAR criteria (European&#xD;
      League Against Rheumatism) aged between 18 to 75 years will be included. This study is a&#xD;
      Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel&#xD;
      active-controlled non-inferiority clinical trial. The eligible patients are randomized in a&#xD;
      1:1 ratio to receive CinnoRA® or Humira®. Every two weeks, 40 mg of either of the drugs will&#xD;
      be administered to each patient subcutaneously along with methotrexate (15 mg/week), folic&#xD;
      acid (1 mg/day), and prednisolone (7.5 mg/day) over six months.&#xD;
&#xD;
      The primary objective of the study is to compare the efficacy of test- adalimumab (CinnoRA®)&#xD;
      and the reference adalimumab (Humira®) in patients with moderately to severely active&#xD;
      rheumatoid arthritis regarding the evaluation of EULAR criteria based on Disease activity&#xD;
      score (DAS).&#xD;
&#xD;
      The secondary objectives of this study are:&#xD;
&#xD;
        -  To further compare the efficacy of test- adalimumab to reference adalimumab&#xD;
&#xD;
        -  To assess the safety of test- adalimumab compared to reference adalimumab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of Adalimumab produced by&#xD;
      CinnaGen company and AbbVie adalimumab in subjects with active rheumatoid arthritis. Patients&#xD;
      with the diagnosis of active rheumatoid arthritis according to EULAR criteria (European&#xD;
      League Against Rheumatism) aged between 18 to 75 years will be included. This study is a&#xD;
      Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel&#xD;
      active-controlled non-inferiority clinical trial. The eligible patients will be randomized in&#xD;
      a 1:1 ratio to receive CinnoRA® or Humira®. Every two weeks, 40 mg of either of the drugs&#xD;
      will be administered to each patient subcutaneously along with methotrexate (15 mg/week),&#xD;
      folic acid (1 mg/day), and prednisolone (7.5 mg/day) over six months.&#xD;
&#xD;
      Physical examinations, vital signs, disease activity, and laboratory parameters will be&#xD;
      evaluated for patients at baseline and 3 and 6-month visits. The incidence of adverse events&#xD;
      at each visit will be recorded based on patients' reports, vital signs, physical&#xD;
      examinations, and laboratory tests.&#xD;
&#xD;
      The trial is reviewed by food and drug administration of Iran. The protocol, case report form&#xD;
      (CRF), information for patients, and informed consent form are submitted to the ethics&#xD;
      committees responsible for review and approval purposes, according to national regulatory&#xD;
      guidelines.&#xD;
&#xD;
      In this study, no patient will be recruited without an informed consent form. All the&#xD;
      informed consent forms which will be signed by the patients will have two copies so that&#xD;
      patients can receive a copy of it.&#xD;
&#xD;
      Determination of sample size:&#xD;
&#xD;
      The outcome measures of this study are changes in composite scores defined by the European&#xD;
      League against Rheumatism (EULAR) and the American College of Rheumatology criterions. The&#xD;
      CinnoRA® group proportion is assumed to be 0.7100 under the null hypothesis of inferiority.&#xD;
      If the response rate of CinnoRA® is at most 18% worse than Humira® (δ = -0.18)&#xD;
      (non-inferiority margin), it will be considered to be non-inferior. Sample size 64 in both&#xD;
      Humira and CinnoRA® groups yields 90% power to detect non-inferiority margin. The&#xD;
      significance level of the test is targeted at 0.0250 (The significance level actually&#xD;
      achieved by this design is 0.0284).&#xD;
&#xD;
      DATA QUALITY ASSURANCE:&#xD;
&#xD;
      CinnaGen Company conducts clinical trials according to procedures that incorporate the&#xD;
      ethical principles of good clinical practice (GCP). Accurate and reliable data collection is&#xD;
      assured by verification and cross-check of the CRFs against the patient's records by clinical&#xD;
      monitors, and the maintenance of a drug-dispensing log by the center.&#xD;
&#xD;
      Principle and coordinating investigators, contract research organization (CRO) coordinators&#xD;
      and sponsor personnel attend the investigator meetings, and at the end, they receive a GCP&#xD;
      certificate.&#xD;
&#xD;
      CRO coordinators and one sponsor attend the Site Initiation Visit (SIV) meetings. Protocol&#xD;
      and GCP principles are reviewed by coordinating investigator of each site, and also the&#xD;
      needed information for completing CRF and Trial Master File (TMF) forms are explained.&#xD;
&#xD;
      Monitoring by CRO will be performed in 30% and 70% of study progress and at the end of the&#xD;
      study. In the monitoring sessions, some sponsor personnel will audit the process. During the&#xD;
      monitoring process, the CRO coordinator will check all CRFs and will confirm them to the&#xD;
      source documents, and for required cases, the query form will be filled out.&#xD;
&#xD;
      The temperature of the refrigerator which containing the medicines will be checked and&#xD;
      recorded by a data logger which will be checked repeatedly by an auditor.&#xD;
&#xD;
      TMF will be checked by CRO coordinator, and it will be rechecked by an auditor. Drug&#xD;
      accountability data and information about the proper time for patients' injections will be&#xD;
      checked by CRO coordinator and rechecked by sponsor personnel.&#xD;
&#xD;
      After monitoring, problems will be reported by monitor and auditor to the trial centers.&#xD;
&#xD;
      Blinding:&#xD;
&#xD;
      The study will be double-blind. The Subjects and those who conduct the study will be unaware&#xD;
      of the state of the patient with regard to the treatment assignments. For this purpose,&#xD;
      subjects will be blinded by using a prefilled syringe of Adalimumab, which is quite similar&#xD;
      to each other. The injection method, injection syringes, and cartridges are totally the same&#xD;
      in both groups. To blind those who conduct the study, the person who delivers or checks the&#xD;
      study drug will be different from those who examine the patients. All drugs packages will be&#xD;
      identified by unique numbers (manufacture code). Finally, the randomization table will be&#xD;
      concealed from research staff by using opaque sealed envelopes.&#xD;
&#xD;
      It should be noted that CRO personnel who enter data into CRF and database and also the&#xD;
      sponsor personnel who monitor data entry will be blinded. The study will be double-blind, and&#xD;
      situations that might warrant breaking the code are defined in the protocol and include&#xD;
      serious adverse events.&#xD;
&#xD;
      Handling of Dropouts or Missing Data:&#xD;
&#xD;
      Since the number of patients who will participate in this clinical trial is limited and&#xD;
      small, the investigator can't perform missing imputation analysis and do statistical analysis&#xD;
      on those patients who are completed the entire study. However, analyses of the adverse events&#xD;
      will be performed on patients who entered the study.&#xD;
&#xD;
      In this study, patients with at least one adverse event will be included in the report. For&#xD;
      each adverse event, data will be summarized using frequencies and percentages and then&#xD;
      classifies according to the body system. They will be reported in the form of incidence rate.&#xD;
      In other words, patients with any number of Adverse Events will be counted only once in this&#xD;
      calculation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2015</start_date>
  <completion_date type="Actual">January 4, 2017</completion_date>
  <primary_completion_date type="Actual">August 17, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The primary variables are the percentage of patients with DAS28-EULAR Good and Moderate Responses at week 24 compared with Humira. Moderate response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is equal to or more than 3.2 or decrement of 0.6-1.2 while patient's DAS score is equal to or below 5.1. Good response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is below 3.2. We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula:&#xD;
DAS28-ESR= (0.56*√(Tender Joint Count)+0.28*√(Swollen Joint Count)+0.7*ln(ESR)+0.014*(global health))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>ACR20, ACR50, and ACR70 Response Rates are considered as respectively an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score from Baseline at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) Disability Index at Week 24.</measure>
    <time_frame>Week 24</time_frame>
    <description>Quality of life is assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score is considered as the main answer. Scores should be between 0 and 3 and the final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability. The disability index of Health Assessment Questionnaire (HAQ) at week 24 is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Adverse Events</measure>
    <time_frame>From the time of first treatment up to the last dose of study treatment; 24 weeks.</time_frame>
    <description>The incidence of adverse events at each visit is recorded based on patients' reports, vital signs, physical examinations, and laboratory tests for systemic safety, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of Participants with Anti-Drug Antibodies (ADA) at Week 24. The ELISA method was used for immunogenicity assessments of adalimumab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Active Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CinnaGen adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AbbVie adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>40 mg Adalimumab every other week is administered subcutaneously to all the patients.</description>
    <arm_group_label>AbbVie adalimumab</arm_group_label>
    <arm_group_label>CinnaGen adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>15 mg Methotrexate is weekly administered to all the patients.</description>
    <arm_group_label>AbbVie adalimumab</arm_group_label>
    <arm_group_label>CinnaGen adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>At least 1 mg Folic acid is daily administered to all the patients.</description>
    <arm_group_label>AbbVie adalimumab</arm_group_label>
    <arm_group_label>CinnaGen adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>7.5 mg Prednisolone is daily administered to all the patients.</description>
    <arm_group_label>AbbVie adalimumab</arm_group_label>
    <arm_group_label>CinnaGen adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18-75 years at the time of signing the informed consent form.&#xD;
&#xD;
          -  Have been diagnosed as having active rheumatoid arthritis (RA) according to The&#xD;
             European League Against Rheumatism criteria&#xD;
&#xD;
          -  moderately to severely active RA for at least six months&#xD;
&#xD;
          -  Patients who have an inadequate response to the treatment with the usual&#xD;
             non-biological regimen for at least 12 weeks according to their investigator judgment.&#xD;
&#xD;
          -  Ability to comprehend and willingness to sign the Informed Consent Form for this&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tuberculosis patient or latent tuberculosis patient (PPD &gt;5mm or abnormal Chest X-ray)&#xD;
&#xD;
          -  Have been treated previously with any biological agents including any tumor necrosis&#xD;
             factor inhibitors (including ORENCIA® (abatacept), KINERET® (anakinra), REMICADE®&#xD;
             (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), SIMPONI®&#xD;
             (golimumab), or Adalimumab).&#xD;
&#xD;
          -  Have a known hypersensitivity to human immunoglobulin proteins or other components of&#xD;
             Humira or test- Adalimumab&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding or planning to become pregnant during the study&#xD;
&#xD;
          -  Have a positive serological test for hepatitis B or hepatitis C or have a known&#xD;
             history of infection with human immunodeficiency virus (HIV) of the past three months.&#xD;
&#xD;
          -  Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound)&#xD;
&#xD;
          -  Have had a serious infection or have been treated with intravenous antibiotics for an&#xD;
             infection within eight weeks or oral antibiotics within two weeks prior to screening&#xD;
&#xD;
          -  Have a history of chronic or recurrent infection&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; two times upper&#xD;
             limit of normal.&#xD;
&#xD;
          -  Hemoglobin &lt;8.5 g/dL.&#xD;
&#xD;
          -  Platelets &lt;125,000/µL.&#xD;
&#xD;
          -  Leukocyte count &lt;3500/µL.&#xD;
&#xD;
          -  Serum Creatinine&gt;2 mg/dl&#xD;
&#xD;
          -  Concomitant use of Prednisolone &gt; 10 mg/day and NSAIDs&#xD;
&#xD;
          -  Treatment with intravenous, intramuscular, intra-articular and oral corticosteroids&#xD;
             within four weeks prior to Day 1 (prednisolone, more than 7.5 mg/daily)&#xD;
&#xD;
          -  Ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL®&#xD;
             (mercaptopurine, 6-MP).&#xD;
&#xD;
          -  Have any of the following conditions:&#xD;
&#xD;
               1. History of congestive heart failure.&#xD;
&#xD;
               2. History of acute myocardial infarction or unstable angina within the previous 12&#xD;
                  months prior to Screening.&#xD;
&#xD;
               3. History of demyelinating disorders (e.g., MS)&#xD;
&#xD;
               4. History of multiple sclerosis&#xD;
&#xD;
               5. History of any malignancy within the previous five years prior to Screening.&#xD;
&#xD;
               6. Any other disease or disorder which, in the opinion of the Investigator, will put&#xD;
                  the subject at risk if they are enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmadreza Jamshidi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alzahra Hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Besat 4 Clinic</name>
      <address>
        <city>Kerman</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghaem Hospital</name>
      <address>
        <city>Mashhad</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Razi Hospital</name>
      <address>
        <city>Rasht</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imam Ali Clinic</name>
      <address>
        <city>Shahr-e kord</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hafez Hospital</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noor Medical Complex</name>
      <address>
        <city>Tabriz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imam Reza Hospital (501 Artesh)</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iran Rheumatism Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loghman Hakim Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965. Review.</citation>
    <PMID>22150039</PMID>
  </reference>
  <reference>
    <citation>den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002 Nov;29(11):2288-98.</citation>
    <PMID>12415583</PMID>
  </reference>
  <reference>
    <citation>Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. Review.</citation>
    <PMID>22473917</PMID>
  </reference>
  <reference>
    <citation>Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004 May;50(5):1400-11.</citation>
    <PMID>15146409</PMID>
  </reference>
  <reference>
    <citation>Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563-71.</citation>
    <PMID>14719195</PMID>
  </reference>
  <reference>
    <citation>Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35-45. Erratum in: Arthritis Rheum. 2003 Mar;48(3):855.</citation>
    <PMID>12528101</PMID>
  </reference>
  <reference>
    <citation>Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727-35.</citation>
    <PMID>7779114</PMID>
  </reference>
  <reference>
    <citation>Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002 May;301(2):418-26.</citation>
    <PMID>11961039</PMID>
  </reference>
  <reference>
    <citation>Khan MOA, Mohiuddin E, Usmanghani K, Hannan A, Akram M, Shah SA, et al. Clinical evaluation of herbal medicines for the treatment of rheumatoid arthritis. Pak J Nutr. 2011;10(1):51-3.</citation>
  </reference>
  <reference>
    <citation>Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine 18E Vol 2 EB: McGraw Hill Professional; 2012.</citation>
  </reference>
  <reference>
    <citation>Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006 Dec;36(3):182-8. Epub 2006 Oct 11. Review.</citation>
    <PMID>17045630</PMID>
  </reference>
  <reference>
    <citation>Yood RA, Guidelines ACoRSoRA. Guidelines for the management of rheumatoid arthritis: 2002 update. 2002.</citation>
  </reference>
  <reference>
    <citation>Lee WY, Chen HY, Chen KC, Chen CY. Treatment of rheumatoid arthritis with traditional chinese medicine. Biomed Res Int. 2014;2014:528018. doi: 10.1155/2014/528018. Epub 2014 Jun 4.</citation>
    <PMID>24991562</PMID>
  </reference>
  <reference>
    <citation>Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711.</citation>
    <PMID>23169319</PMID>
  </reference>
  <reference>
    <citation>Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, Aranda R, Becker JC, Qi K, Dougados M. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009 Apr;36(4):736-42. doi: 10.3899/jrheum.080813. Epub 2009 Feb 27.</citation>
    <PMID>19273451</PMID>
  </reference>
  <reference>
    <citation>Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord. 2014 Dec 23;15:452. doi: 10.1186/1471-2474-15-452.</citation>
    <PMID>25539805</PMID>
  </reference>
  <reference>
    <citation>Hallikainen A, Vartiainen T. Food control surveys of polychlorinated dibenzo-p-dioxins and dibenzofurans and intake estimates. Food Addit Contam. 1997 May-Jun;14(4):355-66. Review.</citation>
    <PMID>9205564</PMID>
  </reference>
  <reference>
    <citation>Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, Wells G. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(4):CD004525. Review. Update in: Cochrane Database Syst Rev. 2013;5:CD004525.</citation>
    <PMID>14584021</PMID>
  </reference>
  <results_reference>
    <citation>Jamshidi A, Gharibdoost F, Vojdanian M, Soroosh SG, Soroush M, Ahmadzadeh A, Nazarinia MA, Mousavi M, Karimzadeh H, Shakibi MR, Rezaieyazdi Z, Sahebari M, Hajiabbasi A, Ebrahimi AA, Mahjourian N, Rashti AM. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Arthritis Res Ther. 2017 Jul 20;19(1):168. doi: 10.1186/s13075-017-1371-4.</citation>
    <PMID>28728599</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <results_first_submitted>June 25, 2019</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CinnaGen Adalimumab</title>
          <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
        </group>
        <group group_id="P2">
          <title>AbbVie Adalimumab</title>
          <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive PPD</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CinnaGen Adalimumab</title>
          <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
        </group>
        <group group_id="B2">
          <title>AbbVie Adalimumab</title>
          <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.29" spread="12.72"/>
                    <measurement group_id="B2" value="47.59" spread="11.48"/>
                    <measurement group_id="B3" value="47.94" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Iran</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient assessment of pain</title>
          <description>We used a visual analogue scale (VAS) ranging from 0 (no pain) to 100 (worst possible pain) to assess the &quot;patient assessment of pain&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.21" spread="23.51"/>
                    <measurement group_id="B2" value="70.22" spread="21.93"/>
                    <measurement group_id="B3" value="68.71" spread="22.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's global assessment of disease activity</title>
          <description>We used a visual analogue scale (VAS) ranging from 0 (no disease activity) to 100 (Extremely active disease) to assess the &quot;Physician's global assessment of disease activity&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.97" spread="17.38"/>
                    <measurement group_id="B2" value="70.44" spread="17.68"/>
                    <measurement group_id="B3" value="69.71" spread="17.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient global assessment of disease activity</title>
          <description>We used a visual analogue scale (VAS) ranging from 0 (no disease activity) to 100 (Extremely active disease) to assess the &quot;patient global assessment of disease activity&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.15" spread="20.35"/>
                    <measurement group_id="B2" value="70.74" spread="22.21"/>
                    <measurement group_id="B3" value="70.44" spread="21.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen joint count, 28 joints</title>
          <units>Swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.96" spread="7.39"/>
                    <measurement group_id="B2" value="9.46" spread="6.98"/>
                    <measurement group_id="B3" value="9.71" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender joint count, 28 joints</title>
          <units>Tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.46" spread="8.23"/>
                    <measurement group_id="B2" value="9.66" spread="7.97"/>
                    <measurement group_id="B3" value="9.56" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR)</title>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.65" spread="21.24"/>
                    <measurement group_id="B2" value="31.12" spread="24.01"/>
                    <measurement group_id="B3" value="31.88" spread="22.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.40" spread="25.98"/>
                    <measurement group_id="B2" value="18.90" spread="23.90"/>
                    <measurement group_id="B3" value="20.12" spread="24.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DAS28-ESR</title>
          <description>We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula:&#xD;
DAS28-ESR= (0.56*√(Tender Joint Count)+0.28*√(Swollen Joint Count)+0.7*ln(ESR)+0.014*(global health))</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.51" spread="1.24"/>
                    <measurement group_id="B2" value="5.47" spread="1.28"/>
                    <measurement group_id="B3" value="5.49" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire (HAQ) Disability Index</title>
          <description>The disability index of Health Assessment Questionnaire (HAQ) is reported which is a self-reported scale to assess the quality of life in rheumatoid arthritis-related studies which includes areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score (between 0 to 3) is considered as the main answer. The final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability.</description>
          <population>Because of the missing data in the health assessment questionnaire, row population differs from the overall.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.25" lower_limit="1.63" upper_limit="3"/>
                    <measurement group_id="B2" value="2.38" lower_limit="1.88" upper_limit="3"/>
                    <measurement group_id="B3" value="2.38" lower_limit="1.75" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24</title>
        <description>The primary variables are the percentage of patients with DAS28-EULAR Good and Moderate Responses at week 24 compared with Humira. Moderate response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is equal to or more than 3.2 or decrement of 0.6-1.2 while patient's DAS score is equal to or below 5.1. Good response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is below 3.2. We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula:&#xD;
DAS28-ESR= (0.56*√(Tender Joint Count)+0.28*√(Swollen Joint Count)+0.7*ln(ESR)+0.014*(global health))</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CinnaGen Adalimumab</title>
            <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
          <group group_id="O2">
            <title>AbbVie Adalimumab</title>
            <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24</title>
          <description>The primary variables are the percentage of patients with DAS28-EULAR Good and Moderate Responses at week 24 compared with Humira. Moderate response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is equal to or more than 3.2 or decrement of 0.6-1.2 while patient's DAS score is equal to or below 5.1. Good response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is below 3.2. We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula:&#xD;
DAS28-ESR= (0.56*√(Tender Joint Count)+0.28*√(Swollen Joint Count)+0.7*ln(ESR)+0.014*(global health))</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24</title>
        <description>ACR20, ACR50, and ACR70 Response Rates are considered as respectively an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score from Baseline at Week 24.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CinnaGen Adalimumab</title>
            <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
          <group group_id="O2">
            <title>AbbVie Adalimumab</title>
            <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24</title>
          <description>ACR20, ACR50, and ACR70 Response Rates are considered as respectively an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score from Baseline at Week 24.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Patients achieving ACR20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Patients achieving ACR50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Patients achieving ACR70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire (HAQ) Disability Index at Week 24.</title>
        <description>Quality of life is assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score is considered as the main answer. Scores should be between 0 and 3 and the final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability. The disability index of Health Assessment Questionnaire (HAQ) at week 24 is reported.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CinnaGen Adalimumab</title>
            <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
          <group group_id="O2">
            <title>AbbVie Adalimumab</title>
            <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire (HAQ) Disability Index at Week 24.</title>
          <description>Quality of life is assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score is considered as the main answer. Scores should be between 0 and 3 and the final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability. The disability index of Health Assessment Questionnaire (HAQ) at week 24 is reported.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Adverse Events</title>
        <description>The incidence of adverse events at each visit is recorded based on patients' reports, vital signs, physical examinations, and laboratory tests for systemic safety, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing.</description>
        <time_frame>From the time of first treatment up to the last dose of study treatment; 24 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CinnaGen Adalimumab</title>
            <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
          <group group_id="O2">
            <title>AbbVie Adalimumab</title>
            <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Adverse Events</title>
          <description>The incidence of adverse events at each visit is recorded based on patients' reports, vital signs, physical examinations, and laboratory tests for systemic safety, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)</title>
        <description>Number of Participants with Anti-Drug Antibodies (ADA) at Week 24. The ELISA method was used for immunogenicity assessments of adalimumab.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CinnaGen Adalimumab</title>
            <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
          <group group_id="O2">
            <title>AbbVie Adalimumab</title>
            <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)</title>
          <description>Number of Participants with Anti-Drug Antibodies (ADA) at Week 24. The ELISA method was used for immunogenicity assessments of adalimumab.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CinnaGen Adalimumab</title>
          <description>CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
        </group>
        <group group_id="E2">
          <title>AbbVie Adalimumab</title>
          <description>Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.&#xD;
Adalimumab: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.&#xD;
Methotrexate: 15 mg Methotrexate is weekly administered to all the patients.&#xD;
Folic Acid: At least 1 mg Folic acid is daily administered to all the patients.&#xD;
Prednisolone: 7.5 mg Prednisolone is daily administered to all the patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritoneal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Inflammation localized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator (PI) may publish results provided a copy of the written publication is received by the sponsor at least 30 days in advance for review and comment. If the parties disagree, PI agrees to meet with the sponsor before submission to resolve any disagreement. It is also agreed that publishing any reports from data is under the condition of the subject's consent. Any reports are highly confidential, and the PI does not have the permission to reveal them without the sponsor's agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nassim Anjidani</name_or_title>
      <organization>CinnaGen Co.</organization>
      <phone>00989125477964</phone>
      <email>anjidani.n@orchidpharmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

